Clinical Trial Update: A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

View source ↗

Summary

A clinical trial to study Hympavzi in congenital hemophilia A or B patients without inhibitors in Japan; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• HYMPAVZI (MARSTACIMAB-HNCQ)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A or B | Status: ACTIVE_NOT_RECRUITING